• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    2.085 -0.005 (-0.24%)
    Streaming Delayed Price Updated: 12:18 PM EDT, May 9, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,395,186
    Open 2.095
    Bid (Size) 2.080 (28)
    Ask (Size) 2.090 (34)
    Prev. Close 2.090
    Today's Range 2.030 - 2.210
    52wk Range 1.830 - 9.160
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive
    ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle... 
    Via Stocktwits
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga

    Performance

    YTD
    -18.9%
    -18.9%
    1 Month
    -13.8%
    -13.8%
    3 Month
    -37.0%
    -37.0%
    6 Month
    -60.7%
    -60.7%
    1 Year
    -73.7%
    -73.7%

    More News

    Read More
    ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
    Via Benzinga
    Exposures Product Safety
    Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
    From ImmunityBio, Inc.
    Via Business Wire
    Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
    From ImmunityBio, Inc.
    Via Business Wire
    Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    ImmunityBio to Host Investor Day
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
    Via Benzinga
    This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
    Via Benzinga
    Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
    Via Benzinga
    ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
    From ImmunityBio, Inc.
    Via Business Wire
    IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
    Via Stocktwits
    Exposures Product Safety
    Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
    From ImmunityBio, Inc.
    Via Business Wire
    Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
    From ImmunityBio, Inc.
    Via Business Wire
    Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 2.085
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 05/09/25 12:18 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 815.56M
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 816M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.